Theriva Biologics sets 1-for-30 reverse split; stock crashes after-hours
Theriva Biologics (TOVX) announced a 1-for-30 reverse stock split, effective December 1, 2026, to meet NYSE listing requirements. Shares will trade on a split-adjusted basis from December 2. The stock crashed in after-hours trading.
How this was made

The 30-second read
Why it matters
The disclosed 1-for-30 ratio and effective dates create a near-term catalyst for price action, spreads, and order-book behavior, with sentiment often turning negative for microcaps.
Market read
A company-specific reverse split is a direct trading catalyst, especially for microcaps where liquidity and compliance narratives can dominate.
What to watch
The article truncates the stated NYSE rationale, so traders should verify the exact compliance trigger and whether additional financing or delisting risk is implied.
Background
Reverse splits reduce share count and can be used to regain or maintain exchange listing compliance.
Ticker impact
Theriva Biologics announced a 1-for-30 reverse split effective Dec. 1, with trading on a split-adjusted basis starting Dec. 2.
Likely downside pressure and higher volatility as the market prices in dilution or continued balance-sheet concerns tied to the reverse split.
The article discloses the company-specific corporate action timing (effective date and first split-adjusted trading day), which typically drives immediate sentiment and technical trading effects for microcaps.
Market effects
Limited spillover, but reinforces that small-cap biotech reverse splits remain a recurring stress signal.
Minimal, primarily affects US microcap trading liquidity and technical levels.
Low, no cross-market linkage indicated.
Counterpoint
The reverse split could be a technical compliance step (e.g., listing requirements) rather than an immediate fundamental deterioration, so selling may be overdone.
Key entities
- companyTheriva Biologics
Announced a 1-for-30 reverse stock split effective Dec. 1, 2026, with split-adjusted trading beginning Dec. 2.
- venueNYSE
The company statement references a need to meet NYSE requirements, though the specific requirement is not fully shown in the excerpt.